



ALABAMA MEDICAID AGENCY

PDL REFERENCE TOOL

Table of Contents

<u>Antigout Agents</u>	Page 2
<u>Antihistamines</u>	Page 3
<u>Anti-infective Agents</u>	Page 4
<u>Behavioral Health</u>	Page 9
<u>Cardiovascular Health</u>	Page 12
<u>Diabetic Agents</u>	Page 17
<u>Disease-Modifying Antirheumatic Drugs</u>	Page 19
<u>Eye, Ear, Nose, and Throat (EENT) Preparations</u>	Page 20
<u>Gastrointestinal Agents</u>	Page 22
<u>Genitourinary Agents</u>	Page 23
<u>Growth Hormone Agents</u>	Page 24
<u>Hormones and Synthetic Substitutes</u>	Page 25
<u>Hereditary Angioedema Agents</u>	Page 26
<u>Immunomodulatory Agents used to treat MS</u>	Page 27
<u>Pain Management & Autonomic Agents</u>	Page 28
<u>Allergy and Respiratory Agents</u>	Page 30
<u>Skin & Mucous Membrane Agents</u>	Page 32
<u>Women's Health</u>	Page 36

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Antigout Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antigout Agents		allopurinol	Aloprim*
		colchicine tablets	Colcrys*
			colchicine capsules
			Gloperba
			Krystexxa
			Mitigare*
		febuxostat	Uloric*
		probenecid	
		probenecid-colchicine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Antihistamines**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
First Generation Antihistamine Agents	none		Karbinal ER
			Ryclora
			Ryvent
		carbinoxamine	
		clemastine	
		diphenhydramine	
		phenylephrine and chlorpheniramine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Anti-infective Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Adamantanes	none	amantadine rimantadine	Flumadine*
Amebicides	none	paromomycin	none
Aminoglycosides	Bethkis*		tobramycin inhalation solution (generic Bethkis)
	Kitabis*		tobramycin inhalation solution (generic Kitabis)
			Arikayce
		tobramycin inhalation solution (generic TOBI)	TOBI*
			TOBI Podhaler
			Zemdri
		amikacin	
		gentamicin	
		neomycin	
		streptomycin	
		tobramycin	
Anthelmintics	none	albendazole	Albenza*
		praziquantel	Biltricide*
			Egaten
			Emverm
		ivermectin	Stromectol*
Antifungals	none		Abelcet
		amphotericin B liposome	AmBisome*
		flucytosine	Ancobon*
			Brexafemme
		casprofungin	Cancidas*
			Cresemba
		fluconazole	Diflucan*
			Eraxis
		miconazole	Mycamine*
		posaconazole	Noxafil*
		itraconazole	Sporanox*
			Tolsura
		voriconazole	Vfend*
			Vivjoa
		amphotericin B	
		griseofulvin	
		ketoconazole	
		nystatin	
		terbinafine	
Antimalarials	none		Coartem
		pyrimethamine	Daraprim*
			Krintafel
		atovaquone and proguanil	Malarone*
		quinine	Qualaquin*
			Sovuna**
		chloroquine	
		hydroxychloroquine	
		mefloquine	
		primaquine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

cc Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antituberculosis Agents	none	ethambutol	Myambutol*
		rifabutin	Mycobutin*
			Paser
			Priftin
		rifampin	Rifadin*
			Sirturo
			Trecator
		cycloserine	
		isoniazid	
		pretomanid	
Cephalosporins	none		Avycaz
		cefotaxime	Claforan*
			Fetroja
		cefixime	Suprax*
		ceftazidime	Tazicef*
			Teflaro
			Zerbaxa
		cefaclor	
		cefadroxil	
		cefazolin	
		cefdinir	
		cefepime	
		cefpodoxime	
		cefprozil	
		ceftriaxone	
		cefuroxime	
		cephalexin	
Chloramphenicol	none	chloramphenicol	
HCV Antivirals	Epclusa ^{CC}	sofosbuvir-velpatasvir ^{CC}	
	Harvoni ^{CC}	ledipasvir-sofosbuvir ^{CC}	
	Mavyret ^{CC}		
	Zepatier ^{CC}		
			Sovaldi
			Viekira Pak
Interferons	none	none	Vosevi
			Intron A
			Pegasys

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Macrolides	none		Dificid
		erythromycin ethylsuccinate	E.E.S.*
		erythromycin ethylsuccinate	EryPed*
		erythromycin lactobionate	Erythrocin Lactobionate*
			Erythrocin Stearate
		azithromycin	Zithromax*
		clarithromycin	
		clarithromycin ER	
Miscellaneous Antibacterials	none	erythromycin base	
			Aemcolo DR
			bacitracin (generic)
		clindamycin	Cleocin*
		colistimethate	Coly-Mycin M*
		daptomycin	Cubicin*
			Dalvance
		vancomycin	Firvanq*
			Kimyrsa
		lincomycin	Lincocin*
			Orbactiv
		bismuth/metronid/tetracycline	Pylera*
			Sivextro
		vancomycin	Vancocin*
Miscellaneous Antimycobacterials	none		Vibativ
			Xenleta
			Xifaxan
		linezolid	Zyvox*
		polymyxin B sulfate	
		dapsone	none
Miscellaneous Antiprotozoals	none	metronidazole	Flagyl*
			Lampit
		atovaquone	Mepron*
		pentamidine	NebuPent*
		pentamidine	Pentam 300*
			Solosec
		benznidazole	
		nitazoxanide	
Miscellaneous Antivirals	Xofluza [†]	tinidazole	
		foscarnet	Foscavir*
			Livtency
Miscellaneous β-Lactams	none		Prevymis
		aztreonam	Azactam*
			Cayston
		cefotetan	Cefotan*
		ertapenem	Invanz*
		cefoxitin	Mefoxin*
		imipenem and cilastatin	Primaxin*
			Recarbrio
Neuraminidase Inhibitors	Relenza [†] Tamiflu ^{†*}		Vabomere
		meropenem	
		oseltamivir [†]	
			Rapivab

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Nucleosides and Nucleotides	none	entecavir	Baraclude*
		adefovir	Hepsera*
			Sitavig
		valganciclovir	Valcyte*
		valacyclovir	Valtrex*
			Veklury
			Vemlidy
		ribavirin	Virazole*
		acyclovir	Zovirax*
		cidofovir	
		famciclovir	
		ganciclovir	
Penicillins	none	amoxicillin and clavulanate	Augmentin*
			Bicillin C-R
			Bicillin L-A
		penicillin G	Pfizerpen*
		ampicillin and sulbactam	Unasyn*
		piperacillin and tazobactam	Zosyn*
		amoxicillin	
		ampicillin	
		dicloxacillin	
		nafticillin	
		oxacillin	
		penicillin VK	
Quinolones	none		Baxdela
		ciprofloxacin	Cipro*
		ciprofloxacin ER	Cipro XR*
		levofloxacin	
		moxifloxacin	
		ofloxacin	
Sulfonamides	none	sulfamethoxazole and trimethoprim	Bactrim*
		sulfamethoxazole and trimethoprim	Bactrim DS*
		sulfadiazine	
Tetracyclines	none	doxycycline	Adoxa*
		doxycycline	Doryx*
			Minocin
		doxycycline	Morgidox*
			Nuzyra
		tigecycline	Tygacil*
		doxycycline	Vibramycin*
			Xerava
		demeclocycline	
		minocycline	
		tetracycline	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Urinary Anti-infectives	none	methenamine	Hiprex*
			Hyophen
		nitrofurantoin and nitrofurantoin macrocrystals	Macrobid*
		nitrofurantoin macrocrystals	Macrochantin*
		fosfomycin	Monurol*
			Phosphasal
		methenamine, methylene blue, phenyl salicylate, sodium phosphate, and hyoscyamine	Uribel*
			Ustell
			Utira-C
		methenamine, sodium phosphate, methylene blue and hyoscyamine	
		trimethoprim	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Behavioral Health**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Alzheimer's Agents	Aricept*	donepezil	
			Adlarity
			Aduhelm
		rivastigmine	Exelon*
			Legembi
		memantine	Namenda*
		memantine	Namenda XR*
			Namzaric
Antidepressants	none	galantamine	Razadyne ER*
		clomipramine	Anafranil*
			Aplenzin
			Auvelity ER
		paroxetine	Brisdelle*
		citalopram	Celexa*
		duloxetine	Cymbalta*
			desvenlafaxine ER
			Drizalma
		venlafaxine	Effexor XR*
			Emsam
			Fetzima
		bupropion	Forfivo XL*
		escitalopram	Lexapro*
			Marplan
		phenelzine	Nardil*
		desipramine	Norpramin*
		nortriptyline	Pamelor*
		paroxetine	Paxil*
		paroxetine	Paxil CR*
			Pexeva
		desvenlafaxine succinate	Pristiq*
		fluoxetine	Prozac*
		mirtazapine	Remeron*
			Sertraline capsules
		doxepin	Silenor*
			Spravato
			Trintellix
		vilazodone	Viibryd*
		bupropion	Wellbutrin SR*
		bupropion	Wellbutrin XL*
		sertraline	Zoloft*
			Zurzuvae
		amitriptyline	
		amitriptyline and chlordiazepoxide	
		amoxapine	
		fluvoxamine	
		imipramine	
		maprotiline	
		nefazodone	
		protriptyline	
		tranylcypromine	
		trazodone	
		trimipramine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Anxiolytics, Sedatives, and Hypnotics: Barbiturates	none		Amytal Sodium
			Sezaby
		pentobarbital	
		phenobarbital	
Anxiolytics, Sedatives, and Hypnotics: Benzodiazepines	none	diazepam rectal kit	
			Alprazolam Intensol
		lorazepam	Ativan*
		triazolam	Halcion*
		clonazepam	Klonopin*
			Loreev XR
		temazepam	Restoril*
		clorazepate	Tranxene*
		alprazolam	Xanax*
		alprazolam ER	Xanax XR*
		chlordiazepoxide	
		diazepam	
		estazolam	
		flurazepam	
		midazolam	
		oxazepam	
Anxiolytics, Sedatives, and Hypnotics: Miscellaneous Agents	none	zolpidem	Ambien*
		zolpidem	Ambien CR*
			Edluar
		tasimelteon	Hetlioz*
		eszopiclone	Lunesta*
		dexmedetomidine	Precedex*
		ramelteon	Rozerem*
		hydroxyzine	Vistaril*
		buspirone	
		droperidol	
		meprobamate	
		zaleplon	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Cerebral Stimulants/ Agents Used for ADHD (Short- and Intermediate-Acting)	Ritalin*	methylphenidate	
		amphetamine-dextroamphetamine	Adderall*
		methamphetamine	Desoxyn*
		dextroamphetamine	Dexedrine*
		amphetamine	Evekeo*
		dexmethylphenidate IR	Focalin*
		methylphenidate	Methylin*
		dextroamphetamine	ProCentra*
		dextroamphetamine	Zenzedi*
Cerebral Stimulants/ Agents Used for ADHD (Long-Acting)	Adderall XR*	amphetamine-dextroamphetamine ER	
	Concerta*		methylphenidate ER (generic)
	Daytrana*		methylphenidate transdermal patch (generic)
	Focalin XR*	dexmethylphenidate ER	
	Vyvanse Capsules	lisdexamfetamine dimesylate	
			Adhansia XR
			Adzenys XR-ODT
		methylphenidate	Aptensio XR*
			Azstarys
			Cotempla XR
			Dyanavel XR
		guanfacine ER	Intuniv*
			Jornay PM
		clonidine ER	Kapvay*
		dextroamphetamine-amphetamine ER	Mydayis ER*
			Qelbree ER
			Quillichew ER
			Quillivant XR
		methylphenidate	Relexxi ER*
		methylphenidate	Ritalin LA*
		atomoxetine	Strattera*
		lisdexamfetamine dimesylate	Vyvanse Chewable Tablets
			Xelstrym
Orexin Receptor Antagonists	none		Belsomra
			Dayvigo
			Quviviq
Wakefulness Promoting Agents	none	armodafinil	Nuvigil*
		modafinil	Provigil*
			Sunosi
			Wakix
			Xyrem
			Xywav

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Cardiovascular Health**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
ACE Inhibitors	none	quinapril	Accupril*
		quinapril and HCTZ	Accuretic*
		ramipril	Altace*
		enalapril	Epaned*
		benazepril	Lotensin*
		benazepril and HCTZ	Lotensin HCT*
		lisinopril	Prinivil*
		lisinopril and HCTZ	Prinzide*
			Qbrelis
		enalapril and HCTZ	Vaseretic*
		enalapril	Vasotec*
		lisinopril and HCTZ	Zestoretic*
		lisinopril	Zestril*
		captopril	
		captopril and HCTZ	
		fosinopril	
		fosinopril and HCTZ	
		moexipril	
		perindopril	
		trandolapril	
Alpha-Adrenergic Blocking Agents	none	doxazosin	Cardura*
			Cardura XL
		prazosin	Minipress*
		terazosin	
Angiotensin II Receptor Antagonists	none	candesartan	Atacand*
		candesartan and HCTZ	Atacand HCT*
		irbesartan and HCTZ	Avalide*
		irbesartan	Avapro*
		olmesartan	Benicar*
		olmesartan and HCTZ	Benicar HCT*
		losartan	Cozaar*
		valsartan	Diovan*
		valsartan and HCTZ	Diovan HCT*
			Edarbi
			Edarbyclor
		losartan and HCTZ	Hyzaar*
		telmisartan	Micardis*
		telmisartan and HCTZ	Micardis HCT*
		olmesartan, amlodipine, and HCTZ	Tribenzor*
		eprosartan	
		telmisartan and amlodipine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antiarrhythmic Agents	none		Multaq
			Nexterone
		disopyramide	Norpace*
			Norpace CR
		amiodarone	Pacerone*
		propafenone	Rythmol SR*
		dofetilide	Tikosyn*
		flecainide	
		mexiletine	
		propafenone	
		quinidine	
Oral Anticoagulants	Eliquis		
	Pradaxa*		dabigatran (generic)
	Xarelto		
		warfarin	
			Savaysa
Beta-Adrenergic Blocking Agents	Hemangeol ^{cc}		
		sotalol	Betapace*
		sotalol	Betapace AF*
		nebivolol	Bystolic*
		carvedilol	Coreg*
		carvedilol	Coreg CR*
		nadolol	Corgard*
		propranolol	Inderal LA*
			Inderal XL
			InnoPran XL
			Kapspargo
			Levatol
		metoprolol	Lopressor*
			Sotylize
		atenolol and chlorthalidone	Tenoretic*
		atenolol	Tenormin*
		metoprolol	Toprol XL*
		bisoprolol and HCTZ	Ziac*
		acebutolol	
		betaxolol	
		bisoprolol	
		labetalol	
		metoprolol and HCTZ	
		nadolol and bendroflumethiazide	
		pindolol	
		timolol	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Calcium-Channel Blocking Agents	none	nifedipine	Adalat CC*
		amlodipine and olmesartan	Azor*
		verapamil	Calan SR*
		diltiazem	Cardizem*
		diltiazem	Cardizem CD*
		diltiazem	Cardizem LA*
		amlodipine and valsartan	Exforge*
		amlodipine, valsartan and HCTZ	Exforge HCT*
			Katerzia
		amlodipine and benazepril	Lotrel*
		diltiazem	Matzim LA*
			Norliqva
		amlodipine	Norvasc*
			Nymalize
		nifedipine	Procardia XL*
		nisoldipine	Sular ER*
		diltiazem	Tiazac*
		verapamil	Verelan*
		verapamil	Verelan PM*
		felodipine	
		isradipine	
		nicardipine	
		nimodipine	
		nisoldipine	
Cardiotonic Agents	none	digoxin	Lanoxin*
			Lanoxin Pediatric
Central Alpha-Agonists	none	clonidine patches	
		clonidine	
		guanfacine	
		methyl dopa	
Direct Vasodilators	none	isosorbide dinitrate-hydralazine	BiDil*
		hydralazine	
		minoxidil	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Diuretics	none		Diuril
		ethacrynic acid	Edecrin*
			Furoscix
		furosemide	Lasix*
		triamterene and HCTZ	Maxzide*
			Thalitone
		amiloride	
		amiloride and HCTZ	
		bumetanide	
		chlorthalidone	
		chlorothiazide	
		hydrochlorothiazide (HCTZ)	
		indapamide	
		methyclothiazide	
		metolazone	
		torsemide	
		triamterene	
Vasopressin Antagonists	none	none	Jynarque
		tolvaptan	Samsca*
Mineralocorticoid (Aldosterone) Receptor Antagonists	none	spironolactone and HCTZ	Aldactazide*
		spironolactone	Aldactone*
			Carospir
		eplerenone	Inspira*
			Kerendia
Miscellaneous Cardiac Drugs	none		Aspruzyo
			Camzyos
		ivabradine	Corlanor*
			Inpefa**
		ranolazine	Ranexa*
			Vyndamax
			Vyndaqel
Miscellaneous Hypotensive Agents	none	none	Vecamyl
Nitrates and Nitrites	Nitro-Bid		
	Nitrostat*	nitroglycerin	
			GoNitro
		isosorbide dinitrate	Isordil*
		nitroglycerin	Nitro-Dur*
		nitroglycerin	Nitrolingual*
		isosorbide mononitrate	
Platelet-aggregation Inhibitors/ Vasodilating Agents, Misc	Brilinta		
		prasugrel	Effient*
		clopidogrel	Plavix*
			Verquvo
		aspirin and dipyridamole	
		cilostazol	
		dipyridamole	
Renin-Angiotensin-Aldosterone System Inhibitors, Misc	Entresto	none	none
Renin Inhibitors	none	aliskiren	Tekturna*
			Tekturna HCT
Bile Acid Sequestrants	none	colestipol	Colestid*
		cholestyramine	Questran*
		cholestyramine	Questran Light*
		colesevelam	Welchol*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Cholesterol Absorption Inhibitors	none	ezetimibe	Zetia*
Fibric Acid Derivatives	none	fenofibrate	Antara*
		fenofibrate	Fenoglide*
		fenofibrate	Lipofen*
		gemfibrozil	Lopid*
		fenofibrate, nanocrystallized	TriCor*
		fenofibric acid	Trilipix*
HMG-CoA Reductase Inhibitors	none		Altoprev
			Atorvaliq
		amlodipine/atorvastatin	Caduet*
			Ezallor
		fluvastatin	Lescol XL*
		atorvastatin	Lipitor*
			Livalo
		simvastatin/ezetimibe	Vytorin*
		simvastatin	Zocor*
			Zypitamag
		lovastatin	
		pravastatin	
		rosuvastatin	
Miscellaneous Antilipemic Agents	none		Evkeeza
			Juxtapid
			Leqvio
		omega-3 ethyl ester	Lovaza*
			Nexletol
			Nexlizet
		icosapent ethyl niacin	Vascepa*
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors	none	none	Praluent
			Repatha

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Diabetic Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Alpha-Glucosidase Inhibitors	none	acarbose miglitol	Precose*
Amylinomimetics	none	none	SymlinPen
Antidiabetic Agents, Miscellaneous	none	mifepristone	Korlym*
			Tzield
Biguanides	none		Glumetza*
			metformin ER (generic Glumetza ER)
		metformin	Riomet*
		metformin	Riomet ER
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	Janumet	none	
	Janumet XR		
	Januvia		
	Jentadueto		
	Jentadueto XR		
	Kazano*		alogliptin-metformin (generic)
	Kombiglyze XR*		saxagliptin-metformin (generic)
	Nesina*		alogliptin (generic)
	Onglyza*		saxagliptin (generic)
	Oseni*		alogliptin-pioglitazone (generic)
	Tradjenta		
			Zituvio*
			sitagliptin (generic)
Incretin Mimetics	Bydureon Bcise ^{cc}	none	
	Byetta ^{cc}		
	Ozempic ^{cc}		
	Rybelsus ^{cc}		
	Trulicity ^{cc}		
	Victoza ^{cc}		
			Mounjaro

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Insulins	Apidra		
	Apidra Solostar		
	Humalog*		insulin lispro
	Humalog Mix		
	Humulin R (U-500)		
	Lantus*		insulin glargine
	Novolog*	insulin aspart	
	Novolog Mix		
	Toujeo* (U-300)		insulin glargine (U-300)
			Admelog
			Afrezza
			Basaglar
			Fiasp
			Levemir
			Lyumjev
			Myxredlin
			Rezvoglar
			Semglee
			Soliqua
			Tresiba
			Xultophy
		Humulin N	
		Humulin R	
		Humulin 70/30	
		insulin lispro protamine 72/25 mix pen	
		Novolin N	
		Novolin R	
		Novolin 70/30	
Meglitinides	none	nateglinide repaglinide	none
Sodium-glucose Co-transporter 2 Inhibitor	Farxiga*	dapagliflozin	
	Invokamet		
	Invokana		
	Jardiance		
	Synjardy		
	Synjardy XR		
	Xigduo XR*		dapagliflozin/metformin ER (generic)
			Glyxambi
			Invokamet XR
			Qtern
			Segluromet
			Steglatro
			Steglujan
			Trijardy XR
Sulfonylureas	none	glimepiride	
		glipizide	Glucotrol*
		glipizide	Glucotrol XL*
		glyburide	Glynase*
		glipizide and metformin	
		glyburide and metformin	
Thiazolidinediones	none	pioglitazone and metformin	Actoplus Met*
		pioglitazone	Actos*
		pioglitazone and glimepiride	Duetact*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Disease-Modifying Antirheumatic Agents			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Disease-Modifying Antirheumatic Agents	Enbrel ^{CC}		
	Humira ^{CC}		
			Actemra
		leflunomide	Arava*
			Avsola
		sulfasalazine	Azulfidine*
			Cibinqo
			Cimzia
			Cosentyx
			Inflectra
			infliximab (generic)
			Kevzara
			Kineret
			Lupkynis
			Olumiant
			Orencia
			Otezla
			Remicade*
			Renflexis
			Rinvoq
			Simponi
			Simponi Aria
			Xeljanz
			Xeljanz XR
			Zymfentra**

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Eye, Ear, Nose, and Throat (EENT) Preparations			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antiallergic Agents	Bepreve*		bepotastine ophthalmic solution (generic)
			Alomide
			Zerviate
		azelastine	
		cromolyn	
		epinastine	
		olopatadine	
Antibacterials	Besivance		
	Cipro HC		
	Zylet		
			AzaSite
		ciprofloxacin	Ciloxan*
			Cortisporin-TC
		neomycin, polymyxin B and dexamethasone	Maxitrol*
		ofloxacin	Ocuflox*
		ciprofloxacin and fluocinolone	Otovel*
		tobramycin and dexamethasone	TobraDex*
			TobraDex ST
		tobramycin	Tobrex*
		moxifloxacin	Vigamox*
		gatifloxacin	
		bacitracin	
		bacitracin and polymyxin B	
		ciprofloxacin and dexamethasone	
		erythromycin base	
		gentamicin	
		levofloxacin	
		neomycin, bacitracin and polymyxin B	
		neomycin, bacitracin, polymyxin B and hydrocortisone	
		neomycin, polymyxin B and gramicidin	
		neomycin, polymyxin B and hydrocortisone	
		ofloxacin	
		polymyxin B and trimethoprim	
		sulfacetamide	
		sulfacetamide and prednisolone	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Intranasal Corticosteroids	Dymista*		azelastine/fluticasone (generic)
	Omnaris		
	Zetonna		
			Beconase AQ
			QNASL
			QNASL Children
			Sinuva
			Xhance
		mometasone nasal spray	
		flunisolide	
		fluticasone	
Vasoconstrictors	none	phenylephrine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Gastrointestinal Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
5-HT ₃ Receptor Antagonists	none		Anzemet
			Sancuso
			Sustol
		granisetron	
		ondansetron	
Antiemetic Antihistamines	none	palonosetron	
		meclizine	Antivert*
			Bonjesta
		doxylamine/pyridoxine	Diclegis*
		trimethobenzamide	Tigan*
Neurokinin-1 Receptor Antagonists	none	dimenhydrinate	
		meclizine	
		prochlorperazine	
			Akynzeo
			Aponvie
Miscellaneous Antiemetics	none		Cinvanti
		aprepitant/fosaprepitant	Emend*
			Barhemsys
Antiulcer Agents and Acid Suppressants	none	dronabinol	Marinol*
		scopolamine	Transderm-Scop*
		dexlansoprazole	Dexilant*
			Konvomep
		esomeprazole magnesium	Nexium*
			omeprazole/sodium bicarbonate (generic)
		lansoprazole	Prevacid*
		omeprazole	Prilosec*
		pantoprazole	Protonix*
			Talicia
			Voquenza
			Voquenza Dual
			Voquenza Triple
		lansoprazole/amoxicillin/clarithromycin	
		rabeprazole	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Genitourinary Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Genitourinary Smooth Muscle Relaxants: Antimuscarinics	Oxytrol		
	Toviaz*	fesoterodine	
		tolterodine	Detrol*
		tolterodine	Detrol LA*
		oxybutynin	Ditropan XL*
			Gelnique
		solifenacin	Vesicare*
		darifenacin	
		flavoxate	
		tropium	
Genitourinary Smooth Muscle Relaxants: Beta-3 Adrenergic Agonists	none		Gemtesa
		mirabegron	Myrbetriq*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Growth Hormone Agents			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Growth Hormone Agents	Genotropin ^{CC}	none	
	Omnitrope ^{CC}		
	Skytrofa ^{CC}		
	Sogroya ^{CC}		
	Zomacton ^{CC}		
			Humatrope
			Ngenla
			Norditropin
			Nutropin
			Saizen
			Serostim

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

ALABAMA MEDICAID AGENCY PDL REFERENCE TOOL – Hormones and Synthetic Substitutes			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Androgens	none		Androderm
		testosterone	AndroGel*
			Aveed
		testosterone cypionate	Depo-Testosterone*
		testosterone	Fortesta*^
			Jatenzo
			Natesto
		testosterone	Testim*
			Testopel
			Tlando
		testosterone	Vogelxo*
			Xyosted
		danazol	
		methyltestosterone	
		oxandrolone	
		testosterone enanthate	

^Fortesta discontinued 5/31/2024.

*Denotes a generic available in at least one dosage form or strength
 **Will be reviewed at a future time when eligible
 ^cDenotes agent is preferred with clinical criteria in place.

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Complement Inhibitors for the Treatment of Hereditary Angioedema			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Complement Inhibitors for the Treatment of Hereditary Angioedema (HAE)	none		Berinert
			Cinryze
		icatibant	Firazyr*
			Haegarda
			Kalbitor
			Orladeyo
			Ruconest
		icatibant	Sajazir*
			Takhzyro

*Denotes a generic available in at least one dosage form or strength
 **Will be reviewed at a future time when eligible
^{cc}Denotes agent is preferred with clinical criteria in place.

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Immunomodulatory Agents used to treat MS			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Immunomodulatory Agents used to treat MS	Avonex		
	Betaseron		
	Copaxone*		glatiramer (generic)
	Rebif		
	Tysabri		
		teriflunomide	Aubagio*
			Bafiertam
			Briumvi
			Extavia
		fingolimod	Gilenya*
			Kesimpta
			Lemtrada
			Mayzent
			Ocrevus
			Plegridy
			Ponvory
			Tascenso ODT
		dimethyl fumarate	Tecfidera*
			Vumerity
			Zeposia

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

ALABAMA MEDICAID AGENCY			
PDL REFERENCE TOOL – Pain Management & Autonomic Agents			
This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A “substitution allowed” physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Centrally Acting Skeletal Muscle Relaxants	none	cyclobenzaprine	Amrix*
			carisoprodol (generic)
		cyclobenzaprine	Fexmid*
		chlorzoxazone	Lorzone*
		methocarbamol	Robaxin*
		metaxalone	
Calcitonin Gene-related Peptide (CGRP) Antagonists	Aimovig ^{CC} Ajovy ^{CC} Qulipta ^{CC} Ubrelvy ^{CC} 	tizanidine	Soma*
			Zanaflex*
		none	
Direct-Acting Skeletal Muscle Relaxants	none	dantrolene	Dantrium*
		dantrolene	Revonto*
			Ryanodex
GABA-derivative Skeletal Muscle Relaxants	none	baclofen	Fleqsuvy*
		baclofen	Gablofen*
			Lioresal Intrathecal
Miscellaneous Skeletal Muscle Relaxants	none		Lyvispah
		orphenadrine/aspirin/caffeine	Norgesic Forte*
Opiate Agonists	none	orphenadrine	
		benzhydrocodone/acetaminophen	Apadaz*
		tramadol	ConZip ER*
		meperidine	Demerol*
		hydromorphone	Dilaudid*
			Dsuvia
			Duramorph
		fentanyl	Fentora*^
			Infumorph
			methadone (generic)
			Methadose*
			Nucynta
			Nucynta ER
			Olinvyk
	Opiate Agonists continued on next page		

^Fentora discontinued 9/30/2024

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Opiate Agonists (continued)	<i>Opiate Agonists continued from previous page</i>		
	none	oxycodone/acetaminophen	Percocet*
			Prolate
		oxycodone	Roxicodone*
			Seglantis
		remifentanil	Ultiva*
		alfentanil	
		codeine	
		codeine/acetaminophen	
		codeine/butalbital/acetaminophen/ caffeine	
		codeine/butalbital/aspirin/caffeine	
		hydrocodone/acetaminophen	
		hydrocodone/ibuprofen	
		ibuprofen/oxycodone	
		levorphanol	
		morphine	
		opium/belladonna	
		oxycodone/aspirin	
		oxymorphone	
		sufentanil	
		tramadol	
		tramadol/acetaminophen	
Opiate Partial Agonists	Sublocade ^{CC}		
	Suboxone ^{*CC}		buprenorphine/naloxone film (generic)
	Zubsolv ^{CC}		
			Belbuca
			Brixadi
			buprenorphine (generic)
		buprenorphine/naloxone tablets ^{CC}	Butrans*
		butorphanol	
Selective Serotonin Agonists	none	nalbuphine	
		pentazocine/naloxone	
		frovatriptan	Frova*
		sumatriptan	Imitrex*
		rizatriptan	Maxalt*
		rizatriptan	Maxalt MLT*
		eletriptan	Relpax*
			Reyvow
			Tosymra
			Zembrace
		zolmitriptan	Zomig*
		zolmitriptan	Zomig ZMT*
		almotriptan	
		naratriptan	
		sumatriptan and naproxen	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Allergy and Respiratory Agents**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Asthma and Allergy Monoclonal Antibodies	Fasenra ^{CC}		Cinqair
	Tezspire ^{CC}		Nucala
	Xolair ^{CC}		
Inhaled Antimuscarinics	Atrovent HFA		
	Incruse Ellipta		
	Spiriva Handihaler*		tiotropium (generic)
	Spiriva Respimat		
			Tudorza Pressair
			Yupelri
		ipratropium bromide	
Inhaled Mast-Cell Stabilizers	none	cromolyn sodium	none
Leukotriene Modifiers		zafirlukast	Accolate*
		montelukast	Singulair*
			zileuton ER (generic)
			Zyflo
Respiratory Corticosteroids	Advair Diskus*		fluticasone/salmeterol (Diskus)
	Advair HFA*		fluticasone/salmeterol (HFA)
	AirDuo Respiclick		
	Arnuity Ellipta		
	Asmanex HFA		
	Asmanex Twisthaler		
	Breo Ellipta*	fluticasone/vilanterol	
	Dulera		
	Flovent Diskus*^	fluticasone	
	Flovent HFA*^	fluticasone	
	Pulmicort Flexhaler		
	QVAR Redihaler		
	Symbicort*		budesonide/formoterol (generic)
			AirDuo Digihaler^
			Airsupra
			Alvesco
			ArmonAir Digihaler^
			Breztri Aerosphere
		budesonide	Pulmicort Respules*
			Trelegy Ellipta

^Proair Digihaler, ArmonAir Digihaler, Airduo Digihaler discontinued 6/1/2024.

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status. A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.			
DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Respiratory Beta-Adrenergic Agonists	Anoro Ellipta		
	Bevespi		
	Combivent Respimat		
	ProAir Digihaler^		
	ProAir Respiclick		
	Serevent Diskus		
	Stiolto Respimat		
	Striverdi Respimat		
	Ventolin HFA*	albuterol HFA	
		arformoterol	Brovana*
			Duaklir Pressair
		formoterol	Perforomist*
		levalbuterol HFA	Xopenex HFA*
		levalbuterol inhalation solution	
		albuterol	
Respiratory Smooth Muscle Relaxants		albuterol/ipratropium	
		metaproterenol	
		terbutaline	
	none		Theo-24
		aminophylline	
		theophylline	

^ Proair Digihaler, ArmonAir Digihaler, Airduo Digihaler discontinued 6/1/2024.

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Skin & Mucous Membrane Agents

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antibacterials	none	mupirocin	Centany*
		clindamycin (vaginal only)	Cleocin*
			Clindesse
			Neo-Synalar
			Nuversa
		metronidazole	Vandazole*
			Xaciatto
			Xepi
Antifungals	none	gentamicin	
		neomycin and polymyxin B	
		ciclopirox	Ciclodan*
			Ertaczo
		sulconazole	Exelderm*
		ketoconazole	Extina*
			Gynazole-1
			Jublia
		tavaborole	Kerydin*
		ciclopirox	Loprox*
		luliconazole	Luzu*
			Mentax
		naftifine	Naftin*
		oxiconazole	Oxistat*
		miconazole/zinc/petrolatum	Vusion*
		clotrimazole	
		clotrimazole and betamethasone	
		econazole	
		ketoconazole	
		miconazole	
		nystatin	
		nystatin and triamcinolone	
		terconazole	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Corticosteroids	None		
		hydrocortisone	Anusol-HC*
		fluticasone	Beser*
			Bryhali
			Capex Shampoo
		clobetasol	Clodan*
		clocortolone	Cloderm*
		hydrocortisone	Cortenema*
			Cortifoam
		fluocinolone	Derma-Smooth/FS*
		betamethasone dipropionate and propylene glycol	Diprolene*
		halcinonide	Halog*
			Impeklo
		triamcinolone	Kenalog*
		halobetasol	Lexette*
		hydrocortisone butyrate	Locoid*
		hydrocortisone butyrate	Locoid lipocream*
		betamethasone valerate	Luxiq*
		clobetasol	Olux*
		clobetasol	Olux-E*
		triamcinolone	Oralene*
			Pandel
			ProctoFoam-HC
		fluocinolone	Synalar*
		clobetasol	Temovate*
		clobetasol and emollient	Temovate Emollient*
			Texacort
		desoximetasone	Topicort*
		clobetasol	Tovet*
		halobetasol	Ultravate*
		fluocinonide	Vanos*
		alclometasone	
		amcinonide	
		betamethasone dipropionate	
		betamethasone valerate	
		desonide	
		diflorasone	
		flurandrenolide	
		hydrocortisone	
		mometasone	
		prednicarbate	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antipruritics and Local Anesthetics	none	lidocaine topical patch	Lidoderm*
		doxepin	Prudoxin*
			Synera
		doxepin	Zonalon*
			ZTLido
		lidocaine	
Antivirals		lidocaine and prilocaine	
	none		
		penciclovir	Denavir*
			Xerese
			Ycanth**
			Zovirax (cream)
Cell Stimulants and Proliferants		acyclovir	Zovirax (ointment)*
	none	none	none
Immunomodulators	Adbry ^{CC}		
	Dupixent ^{CC}		
			Bimzelx
			Ilumya
			Siliq
			Skyrizi
			Sotyktu
			Spevigo
			Stelara
			Taltz
			Tremfya
Keratolytic Agents	none		Bensal HP
			Uramaxin
		urea	
Miscellaneous Anti-inflammatory Agents	Eucrisa ^{CC}	none	none
Miscellaneous Local Anti-infectives	none	silver sulfadiazine	Silvadene*
		silver sulfadiazine	SSD*
		mafenide	Sulfamylon*
		silver nitrate	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Miscellaneous Skin and Mucous Membrane Agents	Elidel*		pimecrolimus (generic)
		podofilox	Condylox*
		calcipotriene	Dovonex*
			Duobrii
			Enstilar
			Filsuvez**
			Hyftor
			Opzelura
			Podocon-25
		tacrolimus	Protopic*
			Rectiv
			Santyl
			Scenesse
		acitretin	Soriatane*
		calcipotriene	Sorilux*
		calcipotriene/betamethasone	Taclonex*
		calcitriol	Vectical*
			Veregen
			Zoryve**
		imiquimod	Zyclara*
Scabicides and Pediculicides	None	formaldehyde	
		podofilox	
		tazarotene	
		crotamiton	Eurax*
			lindane (generic)
		spinosad	Natroba*
		malathion	Ovide*
		ivermectin	Sklice*
		permethrin	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

**ALABAMA MEDICAID AGENCY
PDL REFERENCE TOOL – Women's Health**

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Estrogens/Treatments for menopausal symptoms	Premarin (tablets only)		
	Prempro		
		estradiol and norethindrone	Activella*
		estradiol and norethindrone	Amabelz*
			Angeliq
			Bijuva
		estradiol	Climara*
			Climara Pro
			Combipatch
		estradiol valerate	Delestrogen*
			Depo-Estradiol
		estradiol	Divigel*
			Duavee
			Elestrin
		estradiol	Estrace*
			Estring
		estradiol	Estrogel*
			Evamist
			Femring
		ethinyl estradiol and norethindrone	Jinteli*
			Menest
			Menostar
		estradiol and norethindrone	Mimvey*
		estradiol	Minivelle*
			Prefest
			Premarin (cream and injection)
			Premphase
		estradiol	Vagifem*
			Veozah
		estradiol	Vivelle-Dot*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand
Prenatal Vitamins	Concept DHA*	prenatal vitamins, iron, folic acid, omega-3 fatty acids	
	Concept OB*	prenatal vitamins, iron, folic acid	
	Nestabs		
	Nestabs DHA		
	Thrivite Rx		
	Tricare		
	Vinate II		
	Vitafof FE+ softgel		
	Vitafof Prenatal w/iron Gummies		
	Vitafof-OB		
	Vitafof-OB+DHA		
	Vitafof-One softgel		
	Vitafof Ultra softgel		
			Citranatal 90 DHA
			Citranatal Assure
			Citranatal B-Calm
			Citranatal Bloom
			Citranatal DHA
			Citranatal Harmony
			Enbrace HR
			Extra-Virt Plus DHA
			Marnatal-F
			Nestabs ABC
			Nestabs One
		prenatal vitamins, iron, folic acid	OB Complete*
		prenatal vitamins, iron, folic acid, DHA	OB Complete Caplet*
			OB Complete One
			OB Complete Petite
			OB-Complete Premier
			OB Complete with DHA
			Prenate
			Prenate AM
			Prenate DHA
			Prenate Elite
			Prenate Enhance
			Prenate Essential
			Prenate Mini
			Prenate Pixie
			Prenate Restore
			Prenate Star
			Primacare
			Provida OB
			Select-OB
			Select-OB+DHA
			Tristart DHA
	Prenatal Vitamins continued on next page		

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

Effective 01/02/2025

This PDL reference tool is to aid a prescribing physician with generic availability and preferred product status.
A "substitution allowed" physician signature on a prescription should not require a PA to be obtained if a generic agent is available.

DRUG CLASS	NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
	Preferred Brand	Preferred Generic	Non-Preferred Brand
Prenatal Vitamins (continued)	<i>Prenatal Vitamins continued from previous page</i>		
			Vinate DHA RF
			VitafoI Fe + Docusate
			VP-CH Plus
			VP-CH-PNV
			Zatean-PN Plus

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.